Search

Your search keyword '"Utili, R."' showing total 305 results
Start Over Author "Utili, R." Publication Type Academic Journals
305 results on '"Utili, R."'

1. International experts' practice in the antibiotic therapy of infective endocarditis is not following the guidelines

Author

Tissot-Dupont, H., Casalta, J.P., Gouriet, F., Hubert, S., Salaun, E., Habib, G., Fernandez-Gerlinger, M.P., Mainardi, J.L., Tattevin, P., Revest, M., Lucht, F., Botelho-Nevers, E., Gagneux-Brunon, A., Snygg-Martin, U., Chan, K.L., Bishara, J., Vilacosta, I., Olmos, C., San Román, J.A., López, J., Tornos, P., Fernández-Hidalgo, N., Durante-Mangoni, E., Utili, R., Paul, M., Baddour, L.M., DeSimone, D.C., Sohail, M.R., Steckelberg, J.M., Wilson, W.R., and Raoult, D.

Published
2017
Full Text
View/download PDF

2. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

Author

Harris, P.N.A., McNamara, J.F., Lye, D.C., Davis, J.S., Bernard, L., Cheng, A.C., Doi, Y., Fowler, V.G., Jr., Kaye, K.S., Leibovici, L., Lipman, J., Llewelyn, M.J., Munoz-Price, S., Paul, M., Peleg, A.Y., Rodríguez-Baño, J., Rogers, B.A., Seifert, H., Thamlikitkul, V., Thwaites, G., Tong, S.Y.C., Turnidge, J., Utili, R., Webb, S.A.R., and Paterson, D.L.

Published
2017
Full Text
View/download PDF

7. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor

Author

Tripodi, M.F., Adinolfi, L.E., Ragone, E., Mangoni, E. Durante, Fortunato, R., Iarussi, D., Ruggiero, G., and Utili, R.

Subjects
Gram-positive bacteria -- Risk factors, Gram-positive bacteria -- Research, Streptococcal infections -- Care and treatment, Streptococcal infections -- Research, Endocarditis -- Care and treatment, Endocarditis -- Research, Streptococcus -- Risk factors, Streptococcus -- Research, Health, Health care industry
Published
2004

8. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon nonresponsive chronic hepatitis C: a randomised trial. (Liver)

Author

Adinolfi, L.E., Utili, R., Tonziello, A., and Ruggiero, G.

Subjects
Ribavirin -- Physiological aspects -- Evaluation, Interferon alpha -- Evaluation -- Physiological aspects, Drug therapy, Combination -- Evaluation -- Physiological aspects, Amantadine -- Physiological aspects -- Evaluation, Hepatitis C -- Drug therapy, Health
Abstract

Background: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non- responders. Aims: The safety and long term [...]

Published
2003

33. Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients.

Author

Durante‐Mangoni, E., Vitrone, M., Parrella, A., Andini, R., Iossa, D., Ragone, E., Falco, E., Maiello, C., Utili, R., and Zampino, R.

Subjects
TENOFOVIR, MEDICATION safety, DRUG efficacy, HEPATITIS B treatment, GLOMERULAR filtration rate, HEART transplantation, ANTIVIRAL agents
Abstract

Background Treatment of chronic hepatitis B ( CHB) with polymerase inhibitors is key to prevent disease flares and progression toward advanced liver disease. Efficacy and tolerability of newer agents has been reported anecdotally in transplant recipients. Methods In this prospective, observational study, we assessed outcomes of therapy with tenofovir ( TDF), entecavir ( ETV), and telbivudine (LdT) in 13 heart transplant recipients ( HTR) with CHB. Results Most patients were hepatitis B e antigen negative, had low baseline hepatitis B virus ( HBV) DNA, and normal aminotransferases. Liver biopsy showed a median fibrosis score of 1.5 (range 0-4). Glomerular filtration rate ( GFR) was <50 mL/min in 7 patients (54%). Two patients were started on de novo ETV before transplant. Eleven previously treated patients were switched to TDF ( n = 9) or LdT ( n = 2). Median treatment duration was 33 months (range 1-71). HBV DNA remained suppressed in 6 patients and became undetectable in 5. Aminotransferases went down to the normal range in all patients, with a single flare in 1 patient. One patient lost hepatitis B surface antigen. No cases occurred of hepatic decompensation, hepatocellular carcinoma, or liver-related death. The GFR remained largely stable, and no cases of TDF-related hyper-phosphaturia were observed. Conclusions This study indicates that newer antivirals are effective and safe in HTR with CHB. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

39. P26 HOMOCYSTEINE IN INFECTIVE ENDOCARDITIS

Author

Iossa, D., Molaro, R., D'Amico, F., Pinto, D., Agrusta, F., Mattucci, I., Malgeri, U., Andini, R., Cesaro, F., Senese, A., Farinaro, V., Iorio, V., Cavezza, G., Graziano, C., Battimelli, C., Savinelli, C., Trojaniello, C., Baiano Svizzero, G., Utili, R., and Durante-Mangoni, E.

Published
2013
Full Text
View/download PDF

46. Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

Author

Adinolfi, Luigi, Utili, Riccardo, Andreana, Augusto, Tripodi, Marie-Francoise, Marracino, Marta, Gambardella, Michele, Giordano, Mariagrazia, Ruggiero, Giuseppe, Adinolfi, L E, Utili, R, Andreana, A, Tripodi, M F, Marracino, M, Gambardella, M, Giordano, M, and Ruggiero, G

Abstract

The role of HCV RNA levels and host factors in the severity of liver injury was studied. Enrolled were 298 consecutive liver biopsy-proven chronic hepatitis (CH) C patients (179 men; median age: 52 years, range 19-68; CH, 198; cirrhosis, 100) and 18 chronic hepatitis C with normal ALT. HCV genotypes were: 1a, 4.3%; 1b, 53%; 2a/c, 28%; 3a, 7%; 4, 1.3%, and mixed 6.4%. Serum HCV RNA levels were similar for all genotypes (median: 2.8 x 10(6) eq/ml; range <0.2-69). In patients with chronic hepatitis without cirrhosis, the serum HCV RNA levels reflected the grade of liver necroinflammatory activity (R = 0.45; P < 0.001) and the stage of fibrosis (R = 0.51; P < 0.001), regardless of age, gender, HCV genotype, hepatic steatosis, and hepatic iron overload. Patients with high serum HCV RNA levels (> or =3 x 10(6) eq/ml) had higher ALT values (P < 0.002) than those with lower HCV RNA levels. Patients with normal ALT showed low HCV RNA levels (median: 0.82 x 10(6) eq/ml) and histological features of minimal or mild chronic hepatitis. Cirrhotic patients showed significantly lower levels of viremia than those with chronic hepatitis with a similar HAI. The data of a subgroup of 62 patients with an established time of infection showed that for a similar duration of disease, patients with serum HCV RNA levels > or =3 x 10(6) eq/ml had a significantly higher fibrosis score than those with lower levels. HAI and fibrosis score were significantly higher in patients with HCV RNA levels > or =3 x 10(6) eq/ml and grade 3-4 steatosis than those with lower HCV RNA levels and steatosis grades. The data indicate that the liver damage is correlated with the HCV RNA levels and that a high viral load acts together with steatosis in accelerating the progression of liver injury. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

50. Unorthodox antibiotic combinations including ciprofloxacin against high-level gentamicin resistant enterococci.

Author

Tripodi, M. F., Utili, R., Rambaldi, A., Locatelli, A., Rosario, P., Florio, A., and Ruggiero, G.

Abstract

Development of high-level gentamicin resistance among enterococci represents a serious therapeutic problem as it precludes synergy between aminoglycosides and cell-wall active agents. As part of a search for active antibiotic combinations against enterococci with high-level gentamicin resistance, we tested by the time kill curve method the efficacy of ciprofloxacin combined with ampicillin, trimethoprim-sulphamethoxazole, vancomycin or teicoplanin against ten isolates of Enterococcus faecium, three of Enterococcus casseliflavus and 13 of Enterococcus faecalis that exhibited a MIC of gentamicin > or = 2000 mg/L. Most of the E. faecium were also resistant to ampicillin and to ciprofloxacin. The combination of ciprofloxacin with ampicillin was bactericidal against five of seven E. faecium strains that exhibited a ciprofloxacin MIC < or = 4 mg/L, but was inactive against the three E. faecium that were highly resistant to ciprofloxacin. This combination was also bactericidal against the E. casseliflavus and all the E. faecalis strains. The combination of ciprofloxacin with trimethoprim-sulphamethoxazole was bactericidal against five of the seven E. faecium and seven of the nine E. faecalis strains with a ciprofloxacin MIC < or = 4 mg/L. No bactericidal activity of this combination was seen against the enterococci that were highly resistant to either ciprofloxacin or to trimethoprim-sulphamethoxazole. The combination of ciprofloxacin with glycopeptides was inactive against E. faecium and E. casseliflavus and against E. faecalis, it was either ineffective or antagonistic; in only one case it was bactericidal. Five strains of E. faecium were resistant to all antibiotic combinations tested. [ABSTRACT FROM AUTHOR]

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results